| # | Title | Journal | Year | Citations |
|---|
| 1 | Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort | Lancet Oncology, The | 2014 | 406 |
| 2 | Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: a molecular and clinicopathological study | BMC Cancer | 2015 | 162 |
| 3 | Single nucleotide polymorphism in the 5′ tandem repeat sequences ofthymidylate synthasegene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients | International Journal of Cancer | 2004 | 118 |
| 4 | Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study | Journal of Thoracic Oncology | 2021 | 108 |
| 5 | Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG) | Annals of Oncology | 2014 | 103 |
| 6 | A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma | Cancer | 2005 | 93 |
| 7 | Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC | Journal of Thoracic Oncology | 2022 | 89 |
| 8 | Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial | Annals of Oncology | 2019 | 88 |
| 9 | Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial | Journal of Clinical Oncology | 2023 | 84 |
| 10 | Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel | Clinical Cancer Research | 2018 | 82 |
| 11 | Strategies to design clinical studies to identify predictive biomarkers in cancer research | Cancer Treatment Reviews | 2017 | 80 |
| 12 | Repression of E-cadherin by SNAIL, ZEB1, and TWIST in invasive ductal carcinomas of the breast: a cooperative effort? | Human Pathology | 2011 | 76 |
| 13 | Role of POLE and POLD1 in familial cancer | Genetics in Medicine | 2020 | 76 |
| 14 | Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? | Cancer Chemotherapy and Pharmacology | 2006 | 75 |
| 15 | Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study | Investigational New Drugs | 2013 | 68 |
| 16 | Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation | Bone Marrow Transplantation | 1999 | 67 |
| 17 | Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients | Oncotarget | 2015 | 62 |
| 18 | Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis | European Journal of Cancer | 2009 | 61 |
| 19 | Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. | Journal of Clinical Oncology | 2020 | 56 |
| 20 | DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature. | Journal of Clinical Oncology | 2020 | 48 |
| 21 | Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges | Biomolecules | 2022 | 48 |
| 22 | Prevention of stomal recurrence | | 1996 | 46 |
| 23 | Mismatch Repair Deficiency in Ovarian Carcinoma | American Journal of Surgical Pathology | 2020 | 44 |
| 24 | Genetic counseling program in familial breast cancer: Analysis of its effectiveness, cost and cost‐effectiveness ratio | International Journal of Cancer | 2004 | 41 |
| 25 | Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients | European Journal of Cancer | 2016 | 41 |
| 26 | Prognostic Factors of Peripheral Blood Stem Cell Mobilization with Cyclophosphamide and Filgrastim (r-metHuG-CSF): The CD34+Cell Dose Positively Affects the Time to Hematopoietic Recovery and Supportive Requirements after High-Dose Chemotherapy | Hematology | 1999 | 40 |
| 27 | Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists | Supportive Care in Cancer | 2011 | 40 |
| 28 | Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study | Cancer Epidemiology | 2015 | 39 |
| 29 | Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer | Clinical and Translational Oncology | 2020 | 39 |
| 30 | Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial. | Journal of Clinical Oncology | 2019 | 39 |
| 31 | Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer | International Journal of Cancer | 2008 | 38 |
| 32 | Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study | Breast Cancer Research and Treatment | 2015 | 38 |
| 33 | Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO) | Anti-Cancer Drugs | 2012 | 37 |
| 34 | Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry | Targeted Oncology | 2020 | 37 |
| 35 | What factors may influence psychological well being at three months and one year post BRCA genetic result disclosure? | Breast | 2012 | 36 |
| 36 | Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents | Frontiers in Oncology | 2020 | 32 |
| 37 | Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome | Modern Pathology | 2020 | 29 |
| 38 | ECCO Essential Requirements for Quality Cancer Care: Prostate cancer | Critical Reviews in Oncology/Hematology | 2020 | 29 |
| 39 | Effect of serpinE1 overexpression on the primary tumor and lymph node, and lung metastases in head and neck squamous cell carcinoma | Head and Neck | 2019 | 28 |
| 40 | Unresectable nonmetastatic squamous cell carcinoma of the esophagus managed by sequential chemotherapy (cisplatin and bleomycin) and radiation therapy | Cancer | 1993 | 27 |
| 41 | International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation | Breast Cancer Research and Treatment | 2011 | 27 |
| 42 | Bone pain palliation with strontium-89 in breast cancer patients with bone metastases and refractory bone pain | European Journal of Nuclear Medicine and Molecular Imaging | 1995 | 25 |
| 43 | Leukapheresis components may be cryopreserved at high cell concentrations without additional loss of HPC function | Transfusion | 2000 | 25 |
| 44 | LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) | Annals of Oncology | 2022 | 25 |
| 45 | Pharmacogenetic Study in Rectal Cancer Patients Treated With Preoperative Chemoradiotherapy: Polymorphisms in Thymidylate Synthase, Epidermal Growth Factor Receptor, GSTP1, and DNA Repair Genes | International Journal of Radiation Oncology Biology Physics | 2011 | 24 |
| 46 | Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil | Journal of Cancer Research and Clinical Oncology | 2010 | 23 |
| 47 | Efficacy of nivolumab/ipilimumab in patients with initial or late progression with nivolumab: Updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC). | Journal of Clinical Oncology | 2021 | 23 |
| 48 | SEOM clinical guideline for the management of cutaneous melanoma (2020) | Clinical and Translational Oncology | 2021 | 22 |
| 49 | Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial | Annals of Oncology | 2019 | 21 |
| 50 | The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma | American Journal of Surgical Pathology | 2020 | 21 |
